Aggregation of mAbs is a crucial concern with respect to their safety and efficacy. Among the
various properties of protein aggregates, it is emerging that their size can potentially impact …

Understanding antibody aggregation is of great significance for the pharmaceutical industry.
We studied the aggregation of five different therapeutic monoclonal antibodies (mAbs) with …

Understanding the effects of additives on therapeutic protein stability is of paramount
importance for obtaining stable formulations. In this work, we apply several high-and …

Nonnative aggregation is a common degradation route for therapeutic proteins. Control of
aggregate levels inherently requires control and/or prediction of aggregation rates at …

Purpose Characterization of the monoclonal antibody aggregation process and identification
of stability factors that could be used as indicators of aggregation propensity with an …

The analytical characterization of biopharmaceuticals is a fundamental step in the early
stages of development and prediction of their behavior in bioprocesses. Protein aggregation …

Purpose To develop an analytical platform for the estimation as well as characterization of
aggregates over the complete size spectrum (from invisible monomer to visible precipitates) …

Global aggregation behaviors of three distinct monoclonal antibodies were characterized by
high throughput, multiassay analysis. First, extensive screening of formulations was …

Screening for pharmaceutically viable stability from measurements of thermally induced
protein unfolding and short-term accelerated stress underpins much molecule design …

Purpose To develop a general strategy for optimizing monoclonal antibody (MAb)
formulations. Methods Colloidal stabilities of four representative MAbs solutions were …